Vedolizumab outperforms infliximab in ulcerative colitis patients who fail first-line treatment, achieving better ...

ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness of vedolizumab (Entyvio) versus ustekinumab (Stelara) and of each ...

Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.

Over a 3-year period, MACE occurred in 10.3% of patients taking ustekinumab and 12.2% of patients taking vedolizumab for those with ulcerative colitis (adjusted HR 0.88, 95% CI 0.74-1.05), and in ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Entyvio contains the active ingredient vedolizumab. Entyvio is ...

In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of ...